Last edition
News about "thymic stromal lymphopoietin "
Generate:Biomedicines to Begin Phase 3 Trials of AI-Engineered Asthma Antibody GB-0895
Generate:Biomedicines is set to begin its first global Phase 3 trials for GB-0895, an AI-engineered long-acting anti-TSLP antibody for patients with severe, uncontrolled asthma. The SOLAIRIA-1 and SOLAIRIA-2 studies will evaluate the therapy in about 1,600 patients, marking a key milestone for programmable biology in respiratory care.
Thymic Stromal Lymphopoietin | 02/12/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy